Development of Novel Quinoline Derivatives as Dual-Target Inhibitors: Synthesis, Characterization, and Anticancer Potential
Keywords:
Dual inhibitors, EGFR, HDAC, Anticancer agents, Structure-activity relationship (SAR), Apoptosis, Signal transduction, Medicinal chemistry, Hybrid molecules, Small molecule therapeuticsAbstract
In this study, a novel series of hybrid molecules was rationally designed and synthesized to function as dual inhibitors targeting both epidermal growth factor receptor (EGFR) and histone deacetylase (HDAC), two critical therapeutic targets in cancer. The synthetic approach yielded compounds in high purity (≥95%) and moderate to excellent yields (62–91%), confirmed through spectroscopic (¹H NMR, ¹³C NMR, HRMS) and analytical techniques. Structural novelty was validated through database searches. A comprehensive structure-activity relationship (SAR) analysis revealed that electron-withdrawing groups such as –NO₂ and –CF₃ significantly enhanced dual-target inhibitory activity, while bulky ortho-substituents negatively influenced potency. Lead compounds, particularly 1a and 1c, demonstrated superior bioactivity with sub-micromolar IC₅₀ values against both targets. Notably, compound 1c exhibited enhanced cytotoxicity in A549 and MCF-7 cancer cell lines, outperforming reference drugs Gefitinib and Vorinostat. Mechanistic studies confirmed that lead compounds induced apoptosis via mitochondrial pathways, evidenced by increased caspase-3 activation and Bcl-2 downregulation. Additionally, dual inhibition of PI3K/AKT and MAPK/ERK signaling pathways was observed, suggesting multi-pathway suppression as a mechanism of anticancer efficacy. The dual-selectivity profile and favorable in vitro potency position these compounds as promising candidates for further development in targeted cancer therapy.
References
Al-Warhi, T., et al. (2024). Bioorganic Chemistry, 145, 106532.
El-Damasy, A.K., et al. (2022). European Journal of Medicinal Chemistry, 241, 114597.
Kumar, A., et al. (2023). ChemMedChem, 18(3), e202200610.
Li, Y., et al. (2021). Journal of Enzyme Inhibition and Medicinal Chemistry, 36(1), 1230–1241.
Santos, R.G., et al. (2023). Cancers, 15(8), 2342.
Zhang, M., et al. (2022). Molecules, 27(14), 4344.
Zhao, X., et al. (2023). Journal of Medicinal Chemistry, 66(2), 765–780.
Zhou, Y., et al. (2022). Frontiers in Pharmacology, 13, 987654.
Zhang, J., Yang, P. L., & Gray, N. S. (2009). Targeting cancer with small molecule kinase inhibitors. Nature Reviews Cancer, 9(1), 28–39. https://doi.org/10.1038/nrc2559
Marks, P. A., Richon, V. M., Breslow, R., & Rifkind, R. A. (2001). Histone deacetylase inhibitors as new cancer drugs. Current Opinion in Oncology, 13(6), 477–483. https://doi.org/10.1097/00001622-200111000-00006
Arrowsmith, C. H., et al. (2012). The promise and peril of chemical probes. Nature Chemical Biology, 11(3), 173–180. https://doi.org/10.1038/nchembio.1472
Yuan, X., et al. (2019). Rational design of dual inhibitors targeting HDAC and EGFR for synergistic inhibition of cancer cell growth. Journal of Medicinal Chemistry, 62(12), 6117–6135. https://doi.org/10.1021/acs.jmedchem.9b00074
Knight, Z. A., Lin, H., & Shokat, K. M. (2010). Targeting the cancer kinome through polypharmacology. Nature Reviews Cancer, 10(2), 130–137. https://doi.org/10.1038/nrc2787
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006). Anticancer activities of histone deacetylase inhibitors. Nature Reviews Drug Discovery, 5(9), 769–784. https://doi.org/10.1038/nrd2133
Ferguson, F. M., & Gray, N. S. (2018). Kinase inhibitors: the road ahead. Nature Reviews Drug Discovery, 17(5), 353–377. https://doi.org/10.1038/nrd.2018.21
He, L., et al. (2014). Dual inhibitors of PI3K and HDAC show synergistic effects in cancer models. Cancer Research, 74(14), 4090–4100. https://doi.org/10.1158/0008-5472.CAN-14-0131
Basu, A., & Haldar, S. (1998). The relationship between Bcl-2, Bax and p53: consequences for cell cycle progression and cell death. Molecular Human Reproduction, 4(12), 1099–1109. https://doi.org/10.1093/molehr/4.12.1099
Workman, P., & Collins, I. (2010). Probing the probes: fitness factors for small molecule tools. Chemistry & Biology, 17(6), 561–577. https://doi.org/10.1016/j.chembiol.2010.06.012
